Novartis India Q1 FY27 results: Revenue up 18.6% YoY, PAT at Rs 322.1 mn

Results View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1699.80

prior close

₹1645.90

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%-0.1% vs market

Pharmaceuticals peers, median of 164sector-0.7%-0.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+0.4

15m

+2.8

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.7-0.1-0.7-0.1

Next day

-2.9-0.3-2.6-0.8-2.1

-4.2+1.1-5.2-0.1-4.1

-6.9-0.2-6.7-0.7-6.1

-5.9+0.2-6.1+0.1-6.0

-6.8-0.3-6.5-0.6-6.3

-3.3+2.1-5.4-0.2-3.1

15d

-8.6+4.6-13.2+2.4-11.0

-12.3+5.6-18.0+1.0-13.3

+19.5+7.2+12.3+3.9+15.6

+5.3-4.7+10.0-5.5+10.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results for the quarter ended June 30, 2026. Revenue from operations rose 18.6% YoY to Rs 1,038.1 mn versus Rs 875.5 mn in Q1 FY26. Total income at Rs 1,125.5 mn. Profit before tax up 16% to Rs 431.7 mn. Net profit at Rs 322.1 mn versus Rs 276.2 mn. EPS at Rs 13.05 versus Rs 11.19. Limited review report by BSR and Co LLP was clean with no qualifications. Note 6 flags the ongoing change of control: parent Novartis AG has signed an SPA to sell its 70.68% stake to WaveRise, ChrysCapital and TwoInfinity Partners, awaiting completion.

Likely market impact

Healthy quarter with double digit revenue and profit growth. Major overhang remains the pending 70.68% stake sale by parent Novartis AG.